Ebola Cases Rise In West Africa; Health Workers In Liberia Struggle To Find Work; U.S., China Disagree Over Experimental Drugs

IRIN: Stigma leaves Liberia’s Ebola workers high and dry
“…The majority of the estimated 20,000 or so workers and volunteers who risked their lives during the year-long fight are unable to find work, largely due to lingering stigma and fears about the virus…” (Collins, 6/11).

New York Times: A Chinese Ebola Drug Raises Hopes, and Rancor
“…[Chinese-manufactured MIL77] is a near copy of what many believed was the most promising Ebola therapy: a cocktail of antibodies known as ZMapp, the result of a collaboration between the United States and Canada. … But it has also led to patent infringement concerns by American officials, and to disagreements over when experimental Ebola therapies should be offered to patients only in carefully controlled studies and when they should be made more available for compassionate reasons…” (Fink, 6/11).

U.N. News Centre: Decline in Ebola cases stalls in West Africa, U.N. health agency reports
“The number of Ebola cases in West Africa has increased for the second straight week, with the number of cases that arose from unknown sources of infection highlighting the challenges still faced in finding and eliminating every chain of transmission, according to the World Health Organization (WHO)…” (6/11).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.